Locally advanced cervical cancer (LACC)
Conditions
Interventions
Conventional radiotherapy group:None
Dose-escalation radiotherapy group:Dose-escalation radiation
Sponsors
Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Voluntarily enrolled, with good compliance, able to cooperate with trial observations, and signed a written informed consent form; 2.Diagnosed with LACC (IIB-IVA, FIGO 2018; pathology subtype not limited) through pathology, imaging, and laboratory tests (including biochemistry and tumor markers), with no prior anti-tumor treatment; 3.Subjects aged 18-75 years, with a Karnofsky Performance Status (KPS) score of =70 points; 4.Subjects with an expected survival of more than 6 months; 5.Possess tumor biopsy samples that meet quality control standards and can be prepared for PTC; 6.Good cardiopulmonary, liver, and kidney function, with no contraindications for radiotherapy and chemotherapy.
Exclusion criteria
Exclusion criteria: 1.Poor general condition; patients with severe heart, liver, kidney, and hematologic system diseases who cannot tolerate standard radiotherapy and chemotherapy; 2.Patients with poor compliance and lack of follow-up conditions; 3.Patients with a history of iodine contrast agent allergy, allergic constitution, or currently in an allergic state; 4.Patients with a history of other confirmed malignant tumors; 5.Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical efficacy evaluation; | — |
Secondary
| Measure | Time frame |
|---|---|
| 1-year progression-free survival (PFS), 3-year progressio n-free survival (PFS), 1-year overall survival (OS) and 3-year overall survival (OS); | — |
Countries
China
Contacts
Public ContactLiang Yang
Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine
Outcome results
None listed